229,753 Shares in Medtronic PLC $MDT Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new position in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 229,753 shares of the medical technology company’s stock, valued at approximately $20,009,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Provenance Wealth Advisors LLC raised its holdings in shares of Medtronic by 871.8% during the third quarter. Provenance Wealth Advisors LLC now owns 4,713 shares of the medical technology company’s stock worth $407,000 after acquiring an additional 4,228 shares during the period. Associated Banc Corp bought a new stake in Medtronic in the 3rd quarter valued at $8,371,000. Integrity Alliance LLC. lifted its position in Medtronic by 12.6% in the 3rd quarter. Integrity Alliance LLC. now owns 8,316 shares of the medical technology company’s stock valued at $718,000 after acquiring an additional 928 shares in the last quarter. Integrity Advisory Solutions LLC boosted its stake in Medtronic by 6.6% in the 3rd quarter. Integrity Advisory Solutions LLC now owns 2,996 shares of the medical technology company’s stock worth $259,000 after purchasing an additional 186 shares during the period. Finally, First Nebraska Trust Co acquired a new position in Medtronic in the 3rd quarter worth $6,422,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Up 6.2%

Medtronic stock opened at $105.02 on Thursday. The company has a market cap of $134.34 billion, a price-to-earnings ratio of 25.87, a P/E/G ratio of 2.31 and a beta of 0.56. The firm has a 50-day moving average of $92.21 and a 200-day moving average of $88.39. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 2.7%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported that the SPYRAL AFFIRM real-world study found statistically significant, clinically meaningful blood-pressure reductions six months after treatment with its Symplicity Spyral system. Reductions were seen in office, home, and 24-hour ambulatory readings, without an increase in antihypertensive medications. The findings could strengthen the case for the procedure and support future adoption, though the announcement does not quantify potential sales impact. Article
• Neutral Sentiment: Medtronic and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson’s and caregivers understand deep brain stimulation (DBS). It may raise awareness of an established treatment, but no new product, clinical result, or revenue outlook was announced. Article
• Neutral Sentiment: The company said it will release fiscal Q2 2027 results on November 24. This is a scheduling announcement, with no new financial guidance or operating results. Article
• Negative Sentiment: A report said ETFs were net sellers of MDT, with $110.6 million in outflows on Friday. This is a short-term flow signal and may not indicate a lasting change in investor views. Article
• Negative Sentiment: An analyst roundup cited a consensus price target of $102.88, below the $105.02 reference price in the supplied market data, suggesting limited upside at that level. Article

Insider Activity at Medtronic

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president owned 105,916 shares of the company’s stock, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. UBS Group reissued a “cautious” rating on shares of Medtronic in a research note on Wednesday, October 14th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $92.00 price target on shares of Medtronic in a report on Thursday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Stifel Nicolaus increased their price objective on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings raised Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Eighteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $102.88.

Medtronic Company Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.